The oxysterol synthesizing enzyme CH25H contributes to the development of intestinal fibrosis

Intestinal fibrosis and stenosis are common complications of Crohn’s disease (CD), frequently requiring surgery. Anti-inflammatory strategies can only partially prevent fibrosis; hence, anti-fibrotic therapies remain an unmet clinical need. Oxysterols are oxidized cholesterol derivatives, with important roles in various biological processes. The enzyme cholesterol 25-hydroxylase (CH25H) converts cholesterol to 25-hydroxycholesterol (25-HC), which modulates immune responses and oxidative stress. In human intestinal samples from CD patients we found a strong correlation of CH25H mRNA expression with the expression of fibrosis markers. We demonstrate reduced intestinal fibrosis in mice deficient for the CH25H enzyme using the sodium dextran sulfate (DSS)-induced chronic colitis model. Additionally, using a heterotopic transplantation model of intestinal fibrosis, we demonstrate reduced collagen deposition and lower concentrations of hydroxyproline in CH25H knockouts. In the heterotopic transplant model, CH25H was expressed in fibroblasts. Taken together, our findings indicate an involvement of oxysterol synthesis in the pathogenesis of intestinal fibrosis.

[1]  D. Russell,et al.  Oxysterol Restraint of Cholesterol Synthesis Prevents AIM2 Inflammasome Activation , 2017, Cell.

[2]  N. Jarjour,et al.  RNA-sequencing analysis of lung primary fibroblast response to eosinophil-degranulation products predicts downstream effects on inflammation, tissue remodeling and lipid metabolism , 2017, Respiratory Research.

[3]  C. Buskens,et al.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. , 2017, Journal of Crohn's & colitis.

[4]  J. Cyster,et al.  Peyer's patches: organizing B‐cell responses at the intestinal frontier , 2016, Immunological reviews.

[5]  C. Fiocchi,et al.  Su1869 Submucosal Fibrosis in Ulcerative Colitis Is Linked With Severity and Chronicity of Inflammation , 2016 .

[6]  G. Rogler,et al.  Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis , 2016, Inflammatory bowel diseases.

[7]  A. Vetuschi,et al.  Novel PPAR&ggr; Modulator GED-0507-34 Levo Ameliorates Inflammation-driven Intestinal Fibrosis , 2016, Inflammatory bowel diseases.

[8]  D. Bettenworth,et al.  Reversibility of Stricturing Crohn's Disease—Fact or Fiction? , 2016, Inflammatory bowel diseases.

[9]  G. Rogler,et al.  Cellular and Molecular Mediators of Intestinal Fibrosis , 2015, Journal of Crohn's & colitis.

[10]  Jin Zhong,et al.  Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection , 2015, Journal of Virology.

[11]  G. Rogler.  New Therapeutic Avenues for Treatment of Fibrosis: Can We Learn from Other Diseases? , 2014, Digestive Diseases.

[12]  J. Goldblum,et al.  Fibrosis in ulcerative colitis: mechanisms, features, and consequences of a neglected problem. , 2014, Inflammatory bowel diseases.

[13]  D. Russell,et al.  25-Hydroxycholesterol suppresses interleukin-1–driven inflammation downstream of type I interferon , 2014, Science.

[14]  A. Bittner,et al.  Oxysterols are agonist ligands of RORγt and drive Th17 cell differentiation , 2014, Proceedings of the National Academy of Sciences.

[15]  E. Gold,et al.  25-Hydroxycholesterol acts as an amplifier of inflammatory signaling , 2014, Proceedings of the National Academy of Sciences.

[16]  M. Allez,et al.  The surgical intervention: earlier or never? , 2014, Best practice & research. Clinical gastroenterology.

[17]  C. Feghali-Bostwick,et al.  Fibroblasts in fibrosis: novel roles and mediators , 2014, Front. Pharmacol..

[18]  C. Glass,et al.  25-Hydroxycholesterol Activates the Integrated Stress Response to Reprogram Transcription and Translation in Macrophages* , 2013, The Journal of Biological Chemistry.

[19]  R. Kramann,et al.  Understanding the origin, activation and regulation of matrix‐producing myofibroblasts for treatment of fibrotic disease , 2013, The Journal of pathology.

[20]  G. Rogler,et al.  A New Heterotopic Transplant Animal Model of Intestinal Fibrosis , 2013, Inflammatory bowel diseases.

[21]  J. Duffield,et al.  MicroRNAs are potential therapeutic targets in fibrosing kidney disease: lessons from animal models. , 2013, Drug discovery today. Disease models.

[22]  B. Ryffel,et al.  IL-17A Plays a Critical Role in the Pathogenesis of Liver Fibrosis through Hepatic Stellate Cell Activation , 2013, The Journal of Immunology.

[23]  G. Corazza,et al.  The role of interleukin 17 in Crohn’s disease-associated intestinal fibrosis , 2013, Fibrogenesis & tissue repair.

[24]  M. Ichinose,et al.  25-hydroxycholesterol promotes fibroblast-mediated tissue remodeling through NF-κB dependent pathway. , 2013, Experimental Cell Research.

[25]  G. Cheng,et al.  Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. , 2013, Immunity.

[26]  Kevin A. Robertson,et al.  The Transcription Factor STAT-1 Couples Macrophage Synthesis of 25-Hydroxycholesterol to the Interferon Antiviral Response , 2013, Immunity.

[27]  T. Wynn,et al.  Mechanisms of fibrosis: therapeutic translation for fibrotic disease , 2012, Nature Medicine.

[28]  R. Moritz,et al.  ATF3 protects against atherosclerosis by suppressing 25-hydroxycholesterol–induced lipid body formation , 2012, The Journal of experimental medicine.

[29]  M. Ichinose,et al.  Increased 25‐hydroxycholesterol concentrations in the lungs of patients with chronic obstructive pulmonary disease , 2012, Respirology.

[30]  S. Ng,et al.  Hospitalisations and surgery in Crohn's disease , 2012, Gut.

[31]  L. Karlsson,et al.  Oxysterols direct B-cell migration through EBI2 , 2011, Nature.

[32]  P. Schultz,et al.  Oxysterols direct immune cell migration via EBI2 , 2011, Nature.

[33]  P. Palozza,et al.  Lycopene prevention of oxysterol-induced proinflammatory cytokine cascade in human macrophages: inhibition of NF-κB nuclear binding and increase in PPARγ expression. , 2011, The Journal of nutritional biochemistry.

[34]  Kiwon Park,et al.  Cholesterol 25‐hydroxylase production by dendritic cells and macrophages is regulated by type I interferons , 2010, Journal of leukocyte biology.

[35]  P. Hylemon,et al.  Regulation of Hepatocyte Lipid Metabolism and Inflammatory Response by 25-Hydroxycholesterol and 25-Hydroxycholesterol-3-sulfate , 2010, Lipids.

[36]  C. Creuzot-Garcher,et al.  Effects of oxysterols on cell viability, inflammatory cytokines, VEGF, and reactive oxygen species production on human retinal cells: cytoprotective effects and prevention of VEGF secretion by resveratrol , 2010, European journal of nutrition.

[37]  T. Wynn,et al.  Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent , 2010, The Journal of experimental medicine.

[38]  B. Hinz,et al.  The myofibroblast: paradigm for a mechanically active cell. , 2010, Journal of biomechanics.

[39]  D. Golenbock,et al.  Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide , 2009, Journal of Lipid Research.

[40]  D. Russell,et al.  25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production , 2009, Proceedings of the National Academy of Sciences.

[41]  G. Wolf,et al.  TGF-beta and fibrosis in different organs - molecular pathway imprints. , 2009, Biochimica et biophysica acta.

[42]  C. Fiocchi,et al.  Intestinal fibrosis in IBD—a dynamic, multifactorial process , 2009, Nature Reviews Gastroenterology &Hepatology.

[43]  L. Corcos,et al.  7β-Hydroxycholesterol and 25-hydroxycholesterol-induced interleukin-8 secretion involves a calcium-dependent activation of c-fos via the ERK1/2 signaling pathway in THP-1 cells , 2009, Cell Biology and Toxicology.

[44]  A. Su,et al.  Transcriptional profiling of the effects of 25-hydroxycholesterol on human hepatocyte metabolism and the antiviral state it conveys against the hepatitis C virus , 2009, BMC chemical biology.

[45]  Hua Yang,et al.  Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatment. , 2008, Surgery.

[46]  M. Neurath,et al.  High resolution colonoscopy in live mice , 2006, Nature Protocols.

[47]  L. Beaugerie,et al.  Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery , 2005, Gut.

[48]  G. Rogler,et al.  Regulation of Migration of Human Colonic Myofibroblasts , 2002, Growth factors.

[49]  J. Massagué,et al.  How cells read TGF-β signals , 2000, Nature Reviews Molecular Cell Biology.

[50]  W. Falk,et al.  Interferon‐gamma (IFN‐γ)‐ and tumour necrosis factor (TNF)‐induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)‐induced colitis in mice , 1999, Clinical and experimental immunology.

[51]  D. Russell,et al.  cDNA Cloning of Mouse and Human Cholesterol 25-Hydroxylases, Polytopic Membrane Proteins That Synthesize a Potent Oxysterol Regulator of Lipid Metabolism* , 1998, The Journal of Biological Chemistry.

[52]  G. Rogler,et al.  Mechanisms, Management, and Treatment of Fibrosis in Patients With Inflammatory Bowel Diseases. , 2017, Gastroenterology.

[53]  F. Liu,et al.  Interferon regulator factor 1/retinoic inducible gene I (IRF1/RIG-I) axis mediates 25-hydroxycholesterol-induced interleukin-8 production in atherosclerosis. , 2012, Cardiovascular research.

[54]  J. Massagué.  How cells read TGF-beta signals. , 2000, Nature reviews. Molecular cell biology.